Chee Choo Biography and Net Worth



Mr. CHOO Chee Kong has been our Chairman since the incorporation of our Company in March 2018. Mr. Choo has over 20 years of experience in corporate finance. He is presently the executive vice chairman of CNMC Goldmine Holdings Limited (CNMC Group) which is listed on the SGX-ST (SGX-ST stock code: 5TP) since 2008 where he is responsible for the formulation of the strategic direction and expansion plans as well as the corporate governance of CNMC Group. He previously worked at DBS Bank Ltd of Singapore from 1986 to 2000. In the year 2000, Mr. Choo started his own corporate advisory and stockbroking boutique, Westcomb Financial Group Limited, which he listed on SGX-ST in 2004 (SGX-ST stock code: 5EC) and served as its Chief Executive Officer from 2000 to 2008. He served as an independent director at SGX-ST listed Second Chance Properties Ltd (SGX-ST stock code: 528) from February 2009 to November 2015 and SGX-ST listed FDS Networks Group Ltd (SGX-ST stock code: F07) from June 2008 to March 2015. He also served as a non-executive director at SGX-ST listed Advance SCT Limited (SGX-ST stock code: 5FH) from May 2012 to June 2015. He started his career in October 1981 as a Project Engineer with Esso Singapore Pte Ltd. Mr. Choo received a Bachelor of Engineering in Mechanical Engineering (First Class Honours) from University of Liverpool (United Kingdom) in July 1981 and a Master in Business Administration from the University of Bradford (United Kingdom) in December 1985. We believe that Mr. Choo’s extensive knowledge of our Company as founder and his experience in executive roles across multiple industries qualifies him to serve on our Board

What is Chee Kong Choo's net worth?

The estimated net worth of Chee Kong Choo is at least $400.12 thousand as of May 13th, 2026. Mr. Choo owns 430,324 shares of CytoMed Therapeutics stock worth more than $400,115 as of October 7th. This net worth approximation does not reflect any other investments that Mr. Choo may own. Learn More about Chee Kong Choo's net worth.

How do I contact Chee Kong Choo?

The corporate mailing address for Mr. Choo and other CytoMed Therapeutics executives is , , . CytoMed Therapeutics can also be reached via phone at 65-6250-7738. Learn More on Chee Kong Choo's contact information.

Has Chee Kong Choo been buying or selling shares of CytoMed Therapeutics?

Chee Kong Choo has not been actively trading shares of CytoMed Therapeutics during the past quarter. Most recently, on Wednesday, May 13th, Chee Kong Choo bought 112,000 shares of CytoMed Therapeutics stock. The stock was acquired at an average cost of $1.15 per share, with a total value of $128,800.00. Following the completion of the transaction, the director now directly owns 430,324 shares of the company's stock, valued at $494,872.60. Learn More on Chee Kong Choo's trading history.

Are insiders buying or selling shares of CytoMed Therapeutics?

In the last twelve months, CytoMed Therapeutics insiders bought shares 1 times. They purchased a total of 112,000 shares worth more than $128,800.00. The most recent insider tranaction occured on May, 13th when Director Chee Kong Choo bought 112,000 shares worth more than $128,800.00. Learn More about insider trades at CytoMed Therapeutics.

Information on this page was last updated on 5/13/2026.

Chee Kong Choo Insider Trading History at CytoMed Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/13/2026Buy112,000$1.15$128,800.00430,324View SEC Filing Icon  
See Full Table

Chee Kong Choo Buying and Selling Activity at CytoMed Therapeutics

This chart shows Chee Kong Choo's buying and selling at CytoMed Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CytoMed Therapeutics Company Overview

CytoMed Therapeutics logo
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
Read More

Today's Range

Now: $0.93
Low: $0.86
High: $0.95

50 Day Range

MA: $0.90
Low: $0.78
High: $1.03

2 Week Range

Now: $0.93
Low: $0.68
High: $3.68

Volume

18,564 shs

Average Volume

18,319 shs

Market Capitalization

$11.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.06